News

The NDA was granted Priority Review and has been given a Prescription Drug User Fee Act (PDUFA) action date of Aug. 30, 2017. Celgene completed the NDA submission

APS is a disorder of the immune system, where abnormal antibodies, called antiphospholipid antibodies (aPL) are produced. These bind to beta-2-glycoprotein (beta-2-GPI) in the blood and increase the

The study evaluated the efficacy of Blincyto versus standard of care (SOC) chemotherapy in high-risk adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia

“We are seeing a wave of new legislation being introduced as governments all over the world seek to educate consumers via product packaging,” said Philippe Adam, Vice President

The partnership will utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) – to advance a novel MAPS vaccine targeted to prevent and reduce the

The positive top-line results from the trial showed the treatment effect of axicabtagene ciloleucel in a patient population of 101 having multiple types of aggressive NHL, said Kite

EMD Serono is the biopharmaceutical business of Merck in the US and Canada. The BLA has been accepted for Merck and Pfizer's avelumab to treat patients with locally advanced or mUC with

The $30m funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading US and Israeli biotechnology investors,

Advaxis’ proprietary technology generates innate immune stimulation, alongside potent and sustained T-cell responses. When combined with Sellas’ WT1 antigens, this has the potential to precisely direct an immune